abstract;classe
third men mortal affluent countri tea green tea demonstr promis prevent green tea compon catechin categori properti evid epidemiolog not comprehens strengthen anim vitro evid consumpt tea associ decreas risk evid potenti biolog mechan role green tea prevent review;Positive
inhibitori effect green tea cyclooxygenas inhibitor growth human cell vitro vivo cyclooxygenas cox inhibitor hold promis concern new strategi need approach overcom limit dose cox inhibitor agent complementari mechan effect epigallocatechingal egcg promis agent green tea test alon specif cox inhibitor growth human cell vitro vivo human cell lncap pc cwrrnu egcg ns alon effect growth apoptosi vivo athym nude mice implant androgensensit cwrrnu cell green tea drink water celecoxib ip daili per alon effect growth egcg micromol ns micromol result enhanc cell growth inhibit apoptosi express bax procaspas procaspas polyadpribos polymeras cleavag inhibit pparg inhibit nuclear factorkappab compar addit effect agent alon synerg vivo green tea celecoxib result enhanc growth inhibit prostatespecif antigen level insulinlik growth factori level circul level serum insulinlik growth bind protein compar result singleag synergist addit effect combinatori agent underscor need ration design human clinic trial;Positive
combretastatinchalcon hybrid synthesi cytotox seri alltransarylarylarylpentanedieneon hybrid chalcon combretastatin synthes against panel cell line murin hct colon human epidermoid carcinoma human umbil venous endotheli cell huvec structureact seri reveal dihydroxyphenyl pentanedieneon essenti cytotox alltransdihydroxyphenyl methoxyphenyl trimethoxyphenyl pentanedieneon potent compound seri;Positive
effect acetylsalicyl celecoxib nnitrosodiethylamin induc carcinogenesi esophagus effect nonsteroid antiinflammatori acetylsalicyl celecoxib nnitrosodiethylamin induc carcinogenesi esophagus inhibitori effect celecoxib carcinogenesi pronounc acetylsalicyl manifest decreas neoplast chang tissu esophagus delay malign esophagus eros ulcer gastric mucosa after celecoxib indic celecoxib inhibit nnitrosodiethylamin induc carcinogenesi esophagus;Positive
compar antiprolif antiangiogen apoptosi induc potenti black tea hamster buccal pouch carcinogenesi model efficaci black tea polyphenonb pb btf dimethylbenz anthracen dmba induc hamster buccal pouch hbp carcinogenesi hamster right buccal pouch anim paint dmba hamster receiv anim receiv pb btf dmba paint continu until end anim pb btf alon anim serv untreat control anim sacrif aftesr express cyclin glutathion stransferas pi gstp nuclear kappa nfkappab bcl bax cytochrom caspas caspas polyadpribos polymeras parp cytokeratin vascular endotheli growth vegf analys rtpcr immunohistochem western blot analys dmba anim buccal pouch carcinoma display express cyclin gstp nfkappab cytokeratin vegf bcl decreas express bax cytochrom caspas caspas parp pb btf dmba induc hbp carcinoma modul cell prolifer cell surviv infiltr angiogenesi apoptosi result mechanist potenti black tea greater efficaci btf inhibit hbp carcinogenesi modul molecular target potenti role prevent oral ;Positive
licochalcon suppress migrat invas human hepatocellular carcinoma cell downregul mkk jnk via nfkb mediat urokinas plasminogen activ express hepatocellular cell carcinoma hcc common diagnos taiwan bioactiv compound potenti revers suppress prevent licochalcon lica characterist chalcon licoric root glycyrrhiza inflat report lica antiinflammatori antimicrobi antitumor properti effect lica migrat invas human hcc cell not yet report lica inhibit migratori invas abil skhep hat vgh cell dosedepend manner cell migrat matrigel cell invas assay casein zymographi western blot revers transcriptas polymeras chain immunofluoresc assay lica induc dosedepend inhibit upa activ express well mrna level skhep hat vgh cell lica inhibit express phosphorjnk phosphormkk skhep cell furthermor lica decreas upa level sptreat simkktransfect cell alongsid mark reduct cell migrat invas support notion inhibit mkk jnk result antimetastat effect moreov lica inhibit express nuclear nfkb well bind abil nfkb upa promot role lica suppress metastasi molecular mechan well lica promis antimetastat agent;Positive
curcumin regul colon inhibit pglycoprotein insitu colon perfus model pglycoprotein carri out world vide cell line like caco mdrllcpk mdrmdck invitro result fail produc result invivo curcumin inhibitori action pglycoprotein permeabl irinotecan colon curcumin add intrarect administ nnitroso nmethyl urea induc colon singl pass whole length colon insitu perfus carri out irinotecan influenc pglycoprotein modul like verapamil curcumin serv control perfus irinotecan propronolol red ii induc nmethyl nnitroso urea iii perfus irinotican iv perfus irinotican presenc verapamil pretreat curcumin perfus irinotican estim hplcuv effect permeabl coeffici qrtpcr western blot result confirm decreas express pglycoprotein pgp curcumin colon cell irinotecan cm verapamilcoperfus where curcumin pretreat irinotecan cm cm pglycoprotein inhibitori activ verapamil curcumin enhanc colon permeabl irinotecan safe suitabl pglycoprotein inhibitor irinotecan enhanc therapeut benefit colon ;Positive
design synthesi biolog new inhibitor bax bclxl interact cell describ synthesi seri new molecul triazol moieti compound abil inhibit bax bclxl interact cell bret assay induc cell death deriv exhibit promis activ potent compound acylpyrogallol abt preliminari result demonstr deriv famili attract new molecul potent anticanc activ;Positive
isosuillin isol suillus luteus induc phase arrest apoptosi human hepatoma smmc cell isosuillin natur isol suillus luteus inhibit growth cell line molecular mechan action compound poor understood purpos isosuillin inhibit prolifer induc apoptosi human hepatoma cell line smmc demonstr effect isosuillin cell prolifer apoptosi smmc cell appar normal human coloni format assay dimethylthiazolyl diphenyltetrazolium bromid mtt western blot express phaseregul apoptosisassoci protein level isosuillin smmc cell result indic isosuillin decreas viabil induc phase arrest trigger apoptosi smmccell taken togeth result potenti isosuillin candid ;Positive
hypoxia differenti regul cxcr cxcr signal colon hifalpha cxcr cxcl crucial role metastat signific target hifalpha cxcr cxcl axi prevent dissemin vitro cxcr cxcr mrna protein express human colon carcinoma modul express hypoxia hifalpha colon cell line migrat cell boyden chamber after cxcr inhibit sirna cxcr cxcl neutraligand chalcon cohort colon polyp chromosomeunst carcinoma express cxcr cxcr normal mucosa polyp earlystag carcinoma late stage carcinoma demonstr hypoxia strong induc express cxcr transcript protein cell membran regul hifalpha cxcr express independ hypoxia after transient hypoxia cxcr level stabl cell membran up hour furthermor cxcr express impair cxcl induc akt phosphoryl erk activ unchang cxcr express did not akt erk activ presenc cxcr cxcr sirna signific reduct cell migrat occur irinotecan inhibit cell migrat irinotecan chalcon inhibit demonstr hypoxia upregul cxcr not cxcr express cell cxcr receptor protein level cell membran cell return normoxia up hour addit interest inhibit cxcr signal inhibit hifalpha cxcr cxcl pathway cxcr relev target continu express normox hypox condit cell;Positive
proapoptot properti pomegran juic leukemia cell line pomegran great promis anticanc agent clinic trial pomegran juic pgj induc apoptosi preferenti alter cell cycl leukemia cell line compar nontumor control cell agent not yet fulli elucid leukemia cell line fraction pgj solid phase extract demonstr acetonitril fraction decreas adenosin triphosph atp level leukemia cell line acetonitril fraction activ caspas induc nuclear morpholog characterist apoptosi phase arrest induc acetonitril fraction match phase arrest whole pgj acetonitril fraction content whole pgj low level fraction liquid chromatographi mass spectrometri lcms demonstr acetonitril fraction enrich ellagitannin ellag hydroxycinnam deriv deplet anthocyanin individu compound demonstr ellagitannin punicalagin activ mimick acetonitril fraction bioactiv compon pomegran confin acetonitril fraction pgj enrich ellagitannin hydroxycinnam bioactiv pgj individu compound demonstr ellagitannin punicalagin activ agent highlight compound key bioactiv agent pgj;Positive
target esr subtyp esr esr er modul ovarian ovarian cell express esr esr hormon attract option few effect estrogen opposit effect express esr compar esr indic receptor subtyp oppos effect explain modest nonselect estrogen inhibit clinic practic effect target er subtyp ovarian growth ovarian cell line skov ov express er subtyp er modul sodium phenylaminocarbonyl tetrazolium bismethoxynitro benzen sulfon hydrat xtt assay reveal bishydroxyphenyl methyl piperidinylethoxyphenol hpyrazol dihydrochlorid mpp esr antagonist bishydroxyphenyl propionitril dpn esr agonist suppress cell growth cell line propyl pyrazoletriyl trisphenol ppt esr agonist phenylbistrifluoromethylpyrazolo pyrimidinyl phtpp esr antagonist enhanc cell growth result confirm xenograft model where skov cell inject sc ovariectom mice averag size xenograft dpntreat mpptreat smaller vehicletr addit phosphoakt express skov cell after mpp dpn indic akt pathway involv mpp dpn synergist effect suppress ovarian cell growth indic target er subtyp enhanc hormon women ovarian ;Positive
quinoxalinesubstitut chalcon new inhibitor breast resist protein abcg polyspecif bring seri chalcon substitut quinoxalin unit bring synthes test inhibitor breast resist proteinmedi mitoxantron efflux compound appear effici analog bring substitu naphthyl methylenedioxyphenyl intermedi inhibitori activ naphthyl case methoxi phenyl are produc maxim inhibit molecular model indic electrostat steric contribut potenc naphthyl methylenedioxyphenyl shift are methoxi substitu shift phenyl bring indic prefer polyspecif inhibit;Positive
trilobatin attenu lpsmediat suppress nfkb signal pathway antiinflammatori effect trilobatin flavonoid isol leav lithocarpus polystachyus rehd well molecular mechan trilobatin dosedepend inhibit lipopolysaccharid lps induc mrna express secret proinflammatori cytokin tnf interleukinbeta ilbeta interleukin il raw macrophag inhibit detect trilobatin western blot confirm mechan antiinflammatori effect correl inhibit lps induc inhibitor nuclear factorkappa alpha ikbalpha degrad nuclear factorkappa nfkb phosphoryl addit trilobatin signific inhibit lps induc tnf il mrna protein level mous model result trilobatin potenti inhibit lps induc suppress nfkb signal pathway;Positive
pterostilben suppress oral cell invas inhibit mmp express compound varieti natur plant exhibit antioxid free scaveng abil induc apoptosi cell effect pterostilben oral cell metastasi not clarifi antimetastat properti pterostilben human oral squamous cell carcinoma scc cell pterostilben inhibit migrat invas capac scc cell vitro result zymographi western blot reveal activ protein level mmp urokinasetyp plasminogen activ upa inhibit pterostilben western blot pterostilben inhibit phosphoryl akt erk erk mrna level realtim polymeras chain promot assay conduct inhibitori effect pterostilben mmp upa express scc cell inhibitori effect associ upregul tissu inhibitor metalloproteinas plasminogen activ inhibitor downregul transcript nfkb sp creb signal pathway pterostilben potenti agent against oral metastasi;Positive
natur androgen receptor antagonist induc cellular senesc cell natur occur androgen receptorspecif antagonist atrar aa inhibit transactiv androgen receptor ar androgenmedi growth arexpress human pca cell line aa live cell provok molecular chang ar signal addit deceler nuclear transloc block intramolecular amino carboxi termin interact ar furthermor highresolut confoc fluoresc microscopi speckl format ar line intranuclear mobil receptor decreas bind ar indic impair chromatin recruit ar prostatespecif antigen promot enhanc chromatin immunoprecipit inhibitor nonreceptor tyrosin kinas src akt known interact partner ar level androgen induc cellular senesc nongenom pathway induc cellular senesc aa pp aminochlorophenyl tbutylpyrazolo pyrimidin pyrimidin akt inhibitor inhibitor nonreceptor tyrosin kinas src akt known interact partner ar level androgen induc cellular senesc nongenom pathway induc cellular senesc aa lncap cell aa associ hypophosphoryl retinoblastoma suppressor express pp signal pathway not aa human pca tissu sampl aa ex vivo indic cellular senesc associ express not taken togeth indic aa exhibit novel featur inhibit ar amino carboxytermin interact armedi nuclear activ growth pca cell;Positive
fatti ester phloridzin induc apoptosi human cell alter gene express phloridzin phlorizin phloretin oglucosid known block intestin glucos absorpt anticarcinogen effect phloridzin novel deriv human cell line synthesis novel acyl deriv phloridzin six differ long chain fatti regioselect enzymat acyl candida antarctica lipas antiprolif effect new compound parent compound phloridzin aglycon phloretin six free fatti chemotherapeut sorafenib doxorubicin daunorubicin human hepatocellular carcinoma hepg cell human breast adenocarcinoma mdamb cell acut monocyt leukemia thp cell normal human hepatocyt fatti ester phloridzin inhibit growth carcinoma leukemia cell dose not normal human hepatocyt antiprolif potenc fatti ester phloridzin compar potenc chemotherapeut fatti ester phloridzin inhibit topoisomeras iialpha activ induc phase arrest induc apoptosi via activ caspas decreas atp level mitochondri membran potenti hepg cell cell decosahexaeno dha ester phloridzin gene express rtpcr human target array antiprolif effect dha ester phloridzin down regul antiapoptot gene bcl growth receptor ebfr famili igfr igf pdgfr downstream signal partner pik akt mtor ras raf mapk cell cycl machineri cdks tert topa topb well epigenet regul hdac result fatti ester phloridzin potenti chemotherapeut effect mediat attenu express key protein involv cell cycl regul topoisomeras iialpha activ epigenet mechan cell cycl arrest apoptosi;Positive
synthet chalcon deriv potenti inhibitor secretori phospholipas cyclooxygenas lipoxygenas proinflammatori cytokin arachidon lead generat key lipid mediat play fundament role inflamm inhibit enzym involv arachidon synergist antiinflammatori effect enhanc spectrum activ seri diphenylpropenon deriv antiinflammatori activ involv inhibit secretori phospholipas cyclooxygenas soybean lipoxygenas lipopolysaccharid induc secret interleukin tnf mous raw macrophag result abov mention assay exhibit synthes compound effect inhibitor proinflammatori enzym cytokin result reveal chalcon deriv methlyamino ethanol substitut signific inhibit enzym cytokin molecular dock carri out elucid molecular aspect inhibitori activ compound chalcon deriv serv start point design improv antiinflammatori agent;Positive
verbascosid promot apoptosi regul hipkp signal human role hipkp signal pathway tumorigenesi resist verbascosid vb crc vivo vitro primari human crc sampl normal intestin tissu patient hipk express immunohistochemistri ihc express correl against patient clinicopatholog characterist human crc hct cell implant balb nude mice mice xenograft random vehicl control vb fluorouracil fu hipk bax bcl express ihc vitro effect vb crc cell prolifer apoptosi measur cck assay flow cytometri hipk pp bax bcl measur western blot ihc human crc sampl normal intestin tissu hipk express invers correl duke stage depth invas crc vivo inhibit rate vb crc xenograft accompani express hipk bax decreas bcl express vitro vb inhibit prolifer crc cell line hct ht lovo sw dosedepend manner apoptosi rate vb hct cell ht cell summari vb enhanc protein express proapoptot hipk pp bax decreas antiapoptot bcl express crc cell hipk protein modul phosphoryl status level bax bcl crc vb effect activ hipkp signal pathway result crc cell apoptosi;Positive
natur daucan ester induc apoptosi leukaem cell ros continu research antiprolif agent plant extend interest compound isol ferula communi ferulago campestri new daucan de new deriv ph isol addit six daucan coumarin simpl cytotox activ against panel six human cell line deriv de result moder activ cell line mechan action de abl induc apoptosi concentrationdepend manner sem jurkat cell line de aftesrh ros coincub de ros scaveng cell viabil rosmedi downstream signal essenti antiprolif effect de later incub de induc mitochondri depolar well caspas activ apoptosi mitochondri pathway concomit ros remark decreas mrna express antioxid enzym intracellular gsh content detect cell compar control indic taken togeth result daucan ester induc apoptot cell death rosmedi mechan human leukemia cell;Positive
novel chalcon deriv hypoxiainduc hif inhibitor synthesi antiinvas antiangiogen properti novel seri chalcon deriv synthes biolog activ against hif compound exhibit clear inhibitori effect hif downregul express hifalpha hypox condit meanwhil suppress vegf induc migrat invas hepb huvec cell nontox addit tube format assay demonstr antiangiogenesi activ moreov vivo indic compound retard growth hepb xenograft model cd mmp express tissu final acut intraven well toler nontox up swiss mice support antiinvas antiangiogen potenti compound hif inhibitor;Positive
anthraquinonechalcon hybrid synthesi preliminari antiprolif dnainteract novel anthraquinon chalcon compound synthes start acetylanthraquinon claisenschmidt anticanc potenti against human cell line compound promis activ inhibit hela cell ic low cytotox against healthi mrc cell line effect compound produc cell cycl flow cytometri accumul cell phase dosedepend manner induc caspasedepend apoptosi compound exhibit calf thymus dnabind activ bind constant absorpt titrat mand ctdna ctdna ctdna togeth fluoresc displac design strong minor groov binder;Positive
hydroxynaphthochalcon hnc inhibit tnf induc invas downregul nfkbmediat mmp gene express control metastasi success prevent evid indic natur synthet chalcon exhibit antimetastat activ inhibit nuclear factorkb nfkb precis mechan occur hydroxynaphthochalcon hnc tnf tnf induc mmp mrna express gelatinolyt enzym activ action associ inhibit rela nfkb activ addit hnc inhibit tnf induc invas mdamb breast cell threedimension spheroid invas assay taken togeth demonstr hnc prevent tnf induc cell invas downregul nfkbmediat mmp gene express therebi naphthochalcon potenti effect molecul platform antimetastat agent;Positive
estradiol agonist inhibit human lovo colorectalcanc cell prolifer migrat effect betaestradiol via esr er direct er agonist human lovo cell bioresourc research center cultur redfre dmem sigma unit state effect er agonist cellular prolifer lovo cell erselect agonist subject mtt sigma assay effect er agonist cell western immunoblot out diversif signal pathway motil migrat wound heal assay transwel chamber neuro probe plate tase quantit measur count migrat cell wound area postwound cellular migrationregul urokinasetyp plasminogen activ upa tissuetyp plasminogen activ tpa matrix metalloproteinas mmp human lovo cell gelatin zymographi gelatinolyt activ visual coomassi blue stain result mean se statist student ttest structur compar er agonist lovo cell er agonist mol measur cell viabil mtt assay result betaestradiol er agonist human lovo cell activ upregul protein level inhibit downstream target gene cyclin regul cell prolifer taken togeth demonstr antitumorigenesi effect betaestradiol er agonist compound prove potenti altern human result demonstr betaestradiol er agonist downregul migrationrel protein signal pathway human lovo cell play role betaestradiol er agonistmedi protect activ against addit betaestradiol er agonist dramat inhibit cell migrat express upa tpa mmp well mmp activ lovo cell regul cell metastasi moreov pretreat inhibitor block antimigr effect er agonist lovo cell er agonist impair lovo cell migrat modul migrationrel via suppressor gene direct er prove attract altern human futur;Positive
carotenoid profil antiprolif activ foxtail millet common consum foxtail millet varieti jingu jingu compar term phytochem antioxid properti antiprolif activ cellular antioxid activ caa hepg cell cultiv antiprolif properti against hepg mda cell assay methylen blue assay total content tpc gallic equiv dw jingu jingu varieti ferul chlorogen caffeic pcoumar syring xanthophyl zeaxanthin detect peroxyl scaveng capac foxtail millet jingu jingu mol equiv caa foxtail millet varieti mol quercetin equiv dw prolifer mda hepg cell inhibit dosedepend manner after exposur jingu jingu extract;Positive
inhibit autophagi enhanc curcumin unit light irradi induc growth suppress human cell malign aggress skin carcinoma possess fast propag invas characterist curcumin natur compound biolog activ antiprolif apoptosisacceler impact cell unfortun therapeut activ cur sever hinder extrem low bioavail cooper low cur red unit blue light irradi perform inspect synergist effect apoptosi prolifer autophagi human cell result red unit blue light irradi efficaci synerg cur trigger stressmedi cell death induc apoptosi inhibit cell prolifer meanwhil western blot reveal disposur induc format autophagosom convers inhibit autophagi enhanc apoptosi obstruct cell cycl arrest induc revers prolifer arrest senesc cur red unit blue light irradi generat photochemoprevent effect via enhanc apoptosi trigger autophagi pharmacolog inhibit autophagi convert revers arrest cell senesc damag cell escap program death;Positive
structur effect flavonoid aglycon cell cycl hepg cell activ fisetin quercetin catecholomethyltransferas comt flavonoid abund plant kingdom extens manifold pharmacolog activ highlight cell cycl arrest play key role antiprolif effect differ cell structureact flavonoid poor influenc flavonoid aglycon well cell cycl distribut flavonoid extens cell hepg cell line appli potenti activ inactiv flavonoid test compound diosmetin fisetin apigenin lutelin quercetin provok spectacular extent phase cell cycl arrest inhibit catecholomethyltransferas enzym entacapon decreas antiprolif effect fisetin quercetin geraldol isorhamnetin omethyl fisetin quercetin demonstr antiprolif effect hepg cell compar parent compound result omethyl flavonoid modifi deriv suitabl candid ;Positive
curcumin inhibit ho induc invas migrat human pancreat via suppress erk nfkb pathway curcumin diferuloylmethan natur turmer possess spectrum pharmacolog properti antioxid antitumor metastat activ mechan curcumin suppress metastasi pancreat still not fulli elucid demonstr moder amount hydrogen peroxid ho abl promot pancreat invas curcumin suppress ho induc invas migratori abil human pancreat bxpc panc cell expos ho curcumin nacetylcystein nac scaveng free effect curcumin pancreat cell prolifer mtt assay intracellular ros ros dichlorodihydrofluorecein diacet cellular invas migratori abil transwel matrigel invas assay wound heal assay express matrix metalloproteinas mmp mmp qtpcr western blot mrna protein level activ pextracellular signalregul kinas erk pnuclear factorkb nfkb measur western blot curcumin inhibit cell prolifer dosedepend manner curcumin nac abl inhibit ho induc ros migrat invas decreas express mmp mmp pancreat cell addit hoinduc perk pnfkb bxpc panc cell curcumin nac pd erk inhibitor indic curcumin suppress pancreat migrat invas inhibit ros erk nfkb signal pathway curcumin potenti anticanc agent pancreat ;Positive
halogen naphthochalcon structur naphthopyrazolin antitumor activ halodimethoxyphenyl naphthylpropenon structur pyrazolin prepar vitro anticanc activ chalcon antiprolif low doubledigit micromolar ic against six cell line pyrazolin low singledigit micromolar ic against panel pyrazolin inhibit atpbind cassett efflux transport type pgp bcrp chalcon inhibit bcrp test compound induc accumul ht colon carcinoma cell phase cell cycl interf microtubul factin dynam chalcon induc apoptosi cell aftesrh;Positive
acryloylphenylcarboxamid new breast resist protein abcg modul chalcon easili synthes natur precursor secondari plant deriv biolog activ inhibit abc transport role inhibitor abcg discov abc transport involv multidrug resist inspir synthesi new structur divers deriv typic chalcon moieti chlorid amid linker ringa chalcon result compound cover spectrum substitut pattern allow structureact optim structur featur synthes acryloylphenylcarboxamid inhibitori activ against abcg behavior abcb abcc furthermor promis compound intrins cytotox abil revers abcgmedi multidrug resist ;Positive
preclin valid molecul quininib novel therapeut crc lead death molecular target eg bevacizumab improv surviv rate resist ultim newer requir quininib molecul antiangiogen activ vitro ex vivo vivo screen model quininib quinolinyl vinyl molecul molecular mol inhibit blood vessel zebrafish embryo vitro quininib endotheli tubul format cell migrat unaffect quininib cell surviv quininib ex vivo human crc explant quininib secret il il vegf ena groalpha tnf ilbeta mcp ex vivo quininib well toler mice administ intraperiton everi growth htluc crc xenograft compar vehicl control addit quininib signal alphavbeta integrin fluoresc probe after indic angiogen inhibit furthermor quininib express angiogen gene xenograft support quininib novel therapeut agent crc;Positive
design synthesi cytotox activ certain novel chalcon analog compound seri chalcon analog compound design synthes replac substitut enon ethylen bridg parent chalcon rigid heterocycl moieti substitut amin gave nineteen target compound cytotox activ screen against breast cell well breast normal cell target compound inhibit activ tubulin beta polymer target compound ad broad spectrum excel anticanc activ against mcf hepg compound tubb inhibit activ;Positive
design synthesi activ novel sorafenib analogu bear chalcon unit seri sorafenib deriv nmethylpicolinamideoxi chalcon ao ae synthes nmr ms target compound cytotox against hepg mcf pc cell line compound activ against vegfr kdr braf kinas result indic compound moder good antitumor activ compound well cytotox activ against hepg mcf pc cell line ic activ sorafenib compound good activ vegfr kdr kinas ic structureact sar dock indic replac urea sorafenib chalcon keton improv cytotox activ result halogen br methoxi substitut substitut benefit activ;Positive
molecular mechan antimetastat activ curcumin lead death occur local diseas morbid mortal rate abil cell breakoff primari spread distant organ main proport drugresist cell unpleas sideeffect still challeng curcumin natur compound main bioactiv constitu indian spice turmer indian chines medicin curcumin wellknown therapeut action antiinflammatori antimicrobi antioxid anticanc properti curcumin induc cell apoptosi regul signal pathway arrest cell cycl curcumin therapeut prevent action metastat not yet fulli understood review potenti antimetastat mechan curcumin inhibit transcript signal pathway eg nfkb app stat cytokin eg cxcl cxcl il il proteas eg upa mmps protein kinas eg mapk fak regul mirna eg mir mirb heat shock protein hlj addit synergist action curcumin discuss review;Positive
novel synthet chalcon induc apoptosi nonsmal cell lung cell harbor kras mutat seri novel chalcon synthes claisenschmidt condens tetralon indolecarboxaldehyd human lung cell line harbor kras mutat chalcon induc dosedepend apoptosi cell cycl analys western blot role chalcon interrupt transit cell cycl sar demonstr substitu indol atom anticanc activ chalcon methyl ethyl activ compound ec nm compound activ cell ec nm pc pancreat clr pan cell furthermor compound induc apoptosi lung cell ec did not measur normal lung bronchial epitheli cell hbec dose indic specif cell;Positive
apoptot effect chalcon deriv acetylthiophen human breast cell varieti chalcon demonstr cytotox activ cell line cytotox chalcon deriv acetylthiophen human breast cell line mcf mdamb cell synthes chalcon cytotox tetrazolium dye mtt live dead dapi assay chalcon decreas mcf mdamb cell viabil vitro dose depend manner after ic chalcon display cytotox activ test compound cytotox effect compound confirm live dead assay addit dapi stain reveal compound induc death apoptosi specul chalcon deriv acetylthiophen sourc therapeut agent human breast ;Positive
capsaicin synerg camptothecin induc apoptosi human cell lung via calpain pathway cell lung sclc excel radiat patient show shrinkag even remiss challeng sclc patient inevit relaps not respond line clinic camptothecinbas line sclc patient convent camptothecin recurr sclc poor surviv outcom improv therapeut index camptothecin valuabl sclc extens evid nutrit compound like capsaicin spici compound chili pepper improv anticanc activ chemotherapeut cell line anim model statist capsaicin synerg camptothecin enhanc apoptosi human sclc cell synergist activ camptothecin capsaicin classic variant sclc cell line vivo human sclc xenotranspl chicken chorioallanto membran cam model synergist activ capsaicin camptothecin mediat intracellular calcium calpain pathway foster hope novel nutrit sclc;Positive
design synthesi biolog coupl bioactiv scaffold potenti anticanc agent dual target dihydrofol reductas thioredoxin reductas dihydrofol reductas dhfr thioredoxin reductas trxr enzym involv cell growth surviv diaminodihydrotriazin scaffold wellestablish scaffold dhfr inhibit chalcon report inhibitor trxr novel compound design structur diaminodihydrotriazin chalcon scaffold via diether linker success synthes compound demonstr dual inhibit against dhfr trxr vitro enzym assay compound exhibit antiprolif activ against mcf hct cell potent analog inhibit cellular dhfr trxr activ hct cell compel evid exert anticanc properti via multitarget inhibit cellular level;Positive
ascofuranon inhibit lipopolysaccharid induc via nfkappab ap perk tnf il ilbeta raw macrophag natur fungal compound ascofuranon chloro ee dimethyloxotetrahydrofuranyl methyloctadienyl dihydroxymethylbenzaldehyd mw af isol ascochyta vicia known promot cell cycl arrest inhibit invas cell structur compound ascochlorin asc mw regard antiinflammatori activ lps raw macrophag antiinflammatori activ molecular differ af asc activ af asc uniqu trimethyl oxocyclohexyl structur af uniqu dimethyloxotetrahydrofuran structur af dosedepend inhibit ino cox mrna protein level raw cell addit af suppress mrna express level cytokin tnf il ilbeta rtpcr af clear inhibit nuclear transloc nfkb ap pcjun cytosol space phosphoryl ikb maintain activ nfkb decreas af moreov af suppress bind nfkb inhibit ikba phosphoryl degrad inhibit nuclear transloc immunofluoresc confoc microscopi reveal transloc nfkb ap pcjun decreas af af specif decreas express level perk not express level pp pjnk result af suppress target perk indic af regul lpsstimul nuclear transloc nfkb ap pcjun raw macrophag specif target perk af asc exert effect differ way probabl structur differ allow specif recognit inhibit target mapk result af natur bioactiv compound inflammationmedi patholog diseas;Positive
synthesi biolog novel pyrazol chalcon deriv novel hepatocellular carcinoma therapeut despit second mortal associ sorafenib fdaapprov chemotherapeut agent avail patient improv surviv few month pyrazol chalcon analog compound synthes potenti chemotherapeut agent hepatocellular carcinoma hcc modifi central pyrazol ring differ heteroaryl ring substitut pyrazol differ substitut chalcon moieti produc fouthi variant compound compound cytotox sulforhodamin assay real cell growth track inhibitori ic compound exhibit potent cytotox activ against cell line test cytotox activ wellknown chemotherapeut fu compound chosen panel hcc cell line flow cytometr hcc cell compound demonstr compound cell cycl arrest phase apoptot cell death impair cell growth realtim cell growth surveil consist result western blot hcc cell compound result molecular chang cell cycl protein where level independ level key mitosi cyclin cdk decreas chalcon deriv potent bioactiv modul express cellcycl protein result cellcycl arrest hcc cell line test indic compound preclin candid;Positive
pentabromophenol suppress tgfb signal acceler degrad type ii tgfb receptor via caveolaemedi endocytosi pentabromophenol pbp bromin flame retard bfr consum bfrs exert advers health effect neurotox endocrinedisrupt effect pbp suppress tgfb acceler turnov rate tgfb receptor pbp suppress tgfbmediat cell migrat pai promoterdriven report gene activ smad phosphoryl cell type furthermor pbp abolish tgfbmediat repress ecadherin express addit vimentin express ncadherin fibronectin upregul block tgfb induc epithelialmesenchym transit nmumg cell inhibit not congen tribromophenol triiodophenol tgfb superfamili member play key role regul biolog cell prolifer migrat well result vitro detail pbp modul tgfb signal pbp bfrs polybromin diphenyl ether pbdes addit laboratori mechanist perform bfrs potenti risk tumorigenesi tgfbrelat diseas;Positive
tnf il il express dispar action curcumin against cisplatin induc nephrotox cisplatin regular employ effect chemotherapeut agent type main drawback cisplatin kidney patient mechan believ involv kidney damag inflamm play signific role event curcumin antioxid antiinflammatori effect purpos protect effect curcumin cisplatin induc nephrotox femal random control curcumin cisplatin curcumin plus cisplatin pretreat cisplatin plus curcumin posttreat cisplatin bodi curcumin bodi blood urea nitrogen bun creatinin albumin tnf tnf interleukin il beta il il il express histolog chang th after cisplatin inject acut kidney damag evid bun creatinin level addit cisplatin mark proinflammatori reveal signific tissu level tnf il il decreas il level pretreat curcumin cisplatin induc nephrotox clear evid bun creatinin tnf il il level albumin il level addit support histopatholog kidney posttreat curcumin fail cut down express neglect express il dispar action curcumin after pre posttreat cisplatin induc nephrotox inabl posttreat tnf il besid concurr rise il express renal tissu;Positive
gm arrest flavokawain kava chalcon heroverexpress breast cell herceptin her neu breast predict mortal compris breast flavokawain fka preferenti viabil heroverexpress breast cell line ie skbr mcf her versus less her express ie mcf mdamb fka cytotox breast cell line minim effect growth nonmalign breast epitheli mcfa cell fka induc gm arrest cell cycl heroverexpress breast cell line inhibit cdc cdcc phosphoryl downregul express myt wee lead cdc kinas activ addit fka induc apoptosi skbr cell protein express bim bax decreas express bcl bclx xiap survivin fka downregul protein express her inhibit akt phosphoryl herceptin plus fka lead enhanc growth inhibitori effect her overexpress breast cell line downregul myt wee skp survivin xiap result fka promis novel apoptosi induc block agent herceptin enhanc heroverexpress breast ;Positive
abt enhanc damag apoptosi human tcell acut lymphoblast leukemia molt cell abt belong new anticanc agent name bh mimet abt competit bind surfac hydrophob groov antiapoptot protein bcl famili counteract protect effect natur inhibit prolifer induc apoptosi differ type cell design effect abt human acut lymphoblast leukemia cell vitro cytotox activ agent against molt leukemia cell coulter electr imped comet assay flow cytometri light microscopi western blot techniqu result show abt mark decreas cell viabil damag cell cycl perturb synergist enhanc apoptosi molt cell compar after applic singl agent moreov simultan leukemia cell abt result reduct mitochondri membran potenti protein level upregul bax bcl ratio indic abt promis approach acut lymphoblast leukemia ;Positive
novel diprenyl chalcon inhibit prolifer cell vitro induc cell apoptosi arrest cell cycl phase doubl claisen rearrang synthet strategi total synthesi dimethyl medicagenin compound seri analog prepar novel diprenyl chalcon ring replac azaheterocycl structur twentytwo newli synthes compound confirm nmr nmr esim vitro cytotox target compound cell notic compound exhibit broadspectrum cytotox pc cell mdamb breast cell mda hel erythroleukemia cell ic indic compound induc apoptosi arrest cell cycl phase abov mention cell line compound display potent inhibitori activ against prolifer hel cell ic compound slight induc apoptosi arrest cell cycl phase hel cell preliminari structureact indic cell line pyridinyl essenti cytotox;Positive
ginkgol inhibit migrat breast cell inhibit nemo sumoyl nfkb activ ginkgol ga alkyl crude extract ginkgo biloba leav known anticanc activ mode action not well understood antimigratori activ ga against breast cell molecular mechan behind activ ga mixtur inhibit wound heal mcf mdamb breast cell none compound mixtur cytotox cell line test resazurin assay inhibit nfkb activ hek blue null report cell line furthermor inhibit degrad nuclear klight polypeptid gene enhanc bcell inhibitor alpha ikbalpha sumoyl assay reveal ga inhibit sumoyl nfkb essenti modul nemo molecular dock sumoactiv enzym ga bound activ adenyl site calcul affin kcal mol quantit rtpcr mixtur signific downregul urokinas plasminogen activ upa plasminogen activ inhibitor pai cxc chemokin receptor type cxcr matrix metalloproteinas mmp conclud ga reveal consider antimigratori activ noncytotox indic antimetastat activ low effect explain inhibit nemo sumoyl lead inhibit ikbalpha degrad consequ reduct nfkb activ lead downregul metastasi gene upa pai cxcr mmp;Positive
bisphenol activ egfr erk promot prolifer spheroid format resist egfr pathway inhibit esrneg breast cell evid epidemiolog link environment exposur aggress breast subtyp clinic distinct type breast lethal phenotyp variant breast ibc overexpress epiderm growth receptor egfr her esr er common ibc cell instead solid mass rapid prolifer diffus cell cluster demonstr role adapt antioxid acquir resist egfrtarget ibc environment known induc result perturb signal transduct pathway interest potenti egfr mitogen effect ibc erneg ibc cell subset epa toxcast set effect egfr activ phenotyp assay demonstr endocrinedisrupt bisphenol bpa bisphydroxyphenyl trichloroethan egfr erk signal bpa correspond express sod antiapoptot bcl key antioxid antiapoptot bpa potenti clonogen growth spheroid format vitro reflect ibcspecif patholog characterist furthermor bpa abl attenu inhibitori effect egfr target longerterm anchorageindepend growth assay potenti mechanist environment bpa potenti hyperprolif deathresist phenotyp cell activ mitogen pathway cell addict surviv;Positive
protect effect propofol against tnf induc apoptosi mediat via inhibit ino maintain intracellular ca homeostasi mous hippocamp ht cell inflamm cytokin tnf induc apoptosi neuron cell hypothes propofol attenu tnf induc apoptosi mous hippocamp ht cell mechan mous hippocamp ht cell pretreat propofol tnf cell viabil measur cell count kit cck cell apoptosi flow cytometri effect propofol tnfmodul nitric measur nitrat reductas assay kit intracellular calcium mitochondri membran potenti mmp depolar measur flow cytometri express induc nitric synthas ino ebp homolog protein chop bcell lymphoma bcl famili caspas detect western blot compar control tnf timedepend ht cell apoptosi attenu mol propofol tnf ng induc overexpress ino nitric accumul intracellular ca endoplasm reticulum er lead mitochondri dysfunct effect allevi mol propofol demonstr propofol attenu tnf induc ht apoptosi indic mechan involv ino ca mitochondri dysfunct;Positive
identif novel chalcon deriv inhibit notch signal tcell acut lymphoblast leukemia notch signal ration target harbour notch gain mutat tcell acut lymphoblast leukemia tall design synthet chalconederiv possess notch inhibitori activ low micro molar tall cell line structureact afford chalcon scaffold short term compound result dosedepend decreas notch signal activ halt cell cycl induc apoptosi leukemia cell growth taken togeth indic novel notch inhibitor against notchdepend ;Positive
benzylideneacetophenon deriv induc apoptosi radiationresist human breast cell via benzylideneacetophenon deriv hydroxymethoxyphenyl heptenon jc elicit cytotox effect mdamb human breast cellsradi resist cell mdamb rr dosedepend manner ic jc jcmediat apoptosi confirm subg cell popul jc disrupt mitochondri membran potenti express antiapoptot cell lymphoma protein express proapoptot bclassoci protein lead cleavag caspas caspas poli adpribos polymeras addit jc activ mitogenactiv protein kinas specif inhibitor kinas abrog jc induc apoptot bodi jc level intracellular ros enhanc macromolecular damag via lipid peroxid protein carbonyl strand breakag jc effect against radiationresist human breast cell;Positive
cytotox effect novel naphthylchalcon against cell focus hematolog malign chalcon natur compound describ literatur properti cytotox activ against type search new chemotherapeut agent still necessari cytotox mechan involv cell death induc synthet chalcon differ cell chalcon cell viabil twelv cell line depend manner cytotox against acut leukemia cell interest compound non cytotox normal cell nonhemolyt normal red blood cell chalcon decreas express cell prolifer ki block phase jurkat cell line cell morpholog featur apoptosi latter pattern agaros gel extern phosphatidylserin caspas parp cleavag chalcon mitochondri membran potenti decreas express antiapoptot protein bcl survivin express proapoptot protein bax confirm involv intrins pathway mitochondri permeabl result aif cytochrom endonucleas mitochondria cytosol addit chalcon express fasr induc bid cleavag show involv extrins pathway final chalcon synerg effect cytarabin vincristin result interest compound strong antitumor activ;Positive
anticanc activ hydroxi sulfonamideazobenzen platinum complex cisplatinresist ovarian cell anticanc activ complex wildtyp cisplatinresist acp ovarian cell complex exhibit ic below display activ acp cell line indic not crossresist cisplatin;Positive
synthesi structur nucleas activ cytotox dft molecular dock nitrato bridg homodinuclear cucu znzn complex bipyridin chalcon deriv coligand bind metal ion oo atom antisyn mode metal center complex separ via bridg nitrato distanc structur absorpt spectra support comput densiti theori dft tddft complex exhibit nucleas activ cleav supercoil complex preferenti bind groov pathway complex bind minor groov via hydrolyt pathway complex inhibit topoisomeras relax activ ic molecular dock support groov bind topoisomeras bind complex complex signific cytotox against hela cell line cervic cell line vitro ic calcul compar complex complex induc cell apoptosi laterstag compar complex cell apoptosi topoisomeras inhibit complex enabl potenti candid futur anticanc ;Positive
sechium edul jacq swartz new cultivar antiprolif potenti human cervic hela cell line sechium edul perla negra cultivar recentlyobtain biolog materi whose progenitor edul var nigrum minor edul var amarus silvestri latter report antiprolif activ against hela cell line methanol extract fruit perla negra cultivar biolog activ methanol extract phytochem thin layer chromatographi tlc column chromatographi cc terpen flavonoid compound via perform liquid chromatographi hplc cucurbitacin terpen fraction rutin phlorizidin myricetin quercetin naringenin phloretin apigenin galangin flavonoid fraction biolog activ differ methanol extract hela cell line normal methanol extract inhibit prolifer hela cell ic gml extract ic gml fraction pool inhibit gml biolog effect methanol extract perla negra specif inhibit cell not normal cell unusu featur molecul potenti biomed agent;Positive
centella asiatica modul cachexia associ cytokin cell death leukaem thp cell peripher blood mononuclear cell pbmcs cachexia associ proinflammatori cytokin level centella asiatica asiatica possess antioxid antiinflammatori antitumor potenti modul antioxid cytokin cell death asiatica ethanol leaf extract cle leukaem thp cell normal peripher blood mononuclear cell pbmcs cytotoxc cle scaveng activ cle diphenyl picrylhydrazyl dpph assay glutathion gsh level caspas activ adenosin triphosph atp level luminometri assay level tnf interleukin il ilbeta il enzymelink immunosorb assay cle decreas pbmc viabil cle cle thp viabil cle scaveng activ cle pbmc tnf il level decreas cle pbmc il ilbeta cle decreas cle thp cell cle decreas ilbeta il il level cell line cle gsh caspas activ cle pbmcs decreas cle thp cell cle decreas caspas activ atp level cell line pbmcs thp cell cle prove effect modul antioxid activ cytokin cell death thp cell cle decreas proinflammatori cytokin level antiinflammatori cytokin level allevi cachexia;Positive
compar antiprolif properti ethanol leaf extract anogeissus leiocarpus dc guill perr against hepg hepatocarcinoma cell epidemiolog evid lead death folklor plant reliabl sourc healthrestor principl welldocu search plant activ against diseas continu report laboratorybas evid relev ethanol leaf extract anogeissus leiocarpus al natur quantit flavonoid content involv quercetin gallic standard spectrophotometri cytotox fluorometr propidiumiodidestain antioxid status adenosin triphosph atp level caspas activ mitochondri integr fluorometri luminometri antioxid assay demonstr al possess strong antioxid capac compar compound ascorb butyl hydroxytoluen buttress level quantit extract posttreat indic al modul prolifer hepg carcinoma cell concentrationdepend manner total nuclei area propidiumiodid nuclei area buttress modul cell prolifer al indic cell death apoptosi necrosi possess tendenc activ caspas posttreat mitochondri not mitotox compar al exhibit mitotox taken togeth al possess strong antiprolif activ prospect manag hepatocellular carcinoma deserv ;Positive
apoptosi cell cycl arrest flavokawain ht human colon adenocarcinoma via enhanc ros generat upregul gadd inactiv inhibitor apoptosi protein chalcon exhibit anticanc properti target molecular pathway interest flavokawain fkc natur occur chalcon isol kava piper methysticum forst root extract inhibitori effect fkc growth ht cell mechan action cell viabil ht cell sulforhodamin assay after fkc apoptosi morpholog biochem assay ros generat dichlorofluorescein fluoresc stain superoxid dismutas activ measur spectrophotometr western blot chang protein level fkc mark decreas cell viabil ht cell cell dramat chang cellular nuclear morpholog typic apoptot featur apoptosi correl well extern phosphatidylserin fragment decreas mitochondri membran potenti activ caspas parp cleavag associ ros decreas sod activ protein level xiap ciap ciap downregul gadd upregul after fkc fkc induc cell cycl arrest phase via upregul pindepend manner result evid fkc potenti chemotherapeut colon adenocarcinoma flavokawain inhibit growth ht human colon adenocarcinoma cell flavokawain induc apoptosi ht cell associ ros decreas sod activ flavokawain induc cell cycl arrest phase via upregul ht cellsht cell flavokawain downregul xiap ciap ciap upregul gadd;Positive
novel quinolon chalcon target colchicinebind pocket kill multidrugresist cell inhibit tubulin activ mrp agent target colchicinebind pocket usual minim drugresist issu albeit associ chalconebas compound bind colchicinebind site edibl fruit effect less synthes quinolon chalcon compound methoxyphenyl oxopropenyl quinolinh ctr methoxymethoxyphenyl oxopropenyl quinolinh ctr promis lead ctr effect against differ cell line origin differ tissu larg cellspecif manner ctr ctr revers bind colchicinebind pocket betatubulin interest ctrs effect against multidrugresist cell colchicin paclitaxel vinblastin not ctr overcom multidrugresist abil imped mrp maintain strong inhibit against microtubul activ mice engraft mdamb tripleneg breast cell ctr ctr possess strong anticanc activ alon paclitaxel notabl effect togeth demonstr ctrs effect safe against differ against multidrugresist ;Positive
anticarcinogen activ muntingia calabura leav methanol extract against azoxymethan induc colon involv modul colon antioxid system flavonoid leav muntingia calabura elaeocarpacea tradit medic practic scientif pharmacolog activ anticanc effect not thorough yet object effect memcl against azoxymethan aom induc colon involv endogen antioxid materi male spraguedawley inject intraperiton onc aom except normal receiv salin anim administ oral tween vehicl normal tween vehicl memc after colon sampl histopatholog quantif aberr crypt foci colon antioxid level memc subject hplc extract exert signific anticarcinogenesi activ indic decreas total aberr crypt format antioxid activ colon tissu antioxid ie superoxid dismutas sod catalas cat glutathion gsh ie malonaldehyd mda level hplc demonstr presenc rutin muntingia calabura leav exert anticanc effect against aom induc colon via action flavonoid colon tissu antioxid activ;Positive
apoptosisinduc effect preapoptot gallic simul comet assay techniqu cell line pc demonstr effect gallic ga molecul cell line pc comet assay alkalin electrophoresi techniqu effect apoptot bad bclassoci death promot bak bcl homolog antagonist killer bim bcllike protein via simul auto dock gromac softwar mtt assay pc cell ic ga around ic pc cell comet pictur alkalin electrophoresi analys casp version softwar result thereaft analys spss version statist softwar ic ga ratio tail head alkalin electrophoresi below ic ga measur percent result preapoptot bad bak bim perform simul absenc presenc ga ga protein structur instabl bad protein effect ga explain creation hydrogen bond protein ga compound plant suppress cell growth induc apoptosi pc cell ic apoptot properti ga induc preapoptot ;Positive
effect nonsteroid antiinflammatori recurr risk hepatocellular carcinoma metaanalysi nonsteroid antiinflammatori nsaid risk type epidemiolog evid associ nsaid intak risk hepatocellular carcinoma hcc controversi prevent benefit nsaid hcc simultan search databas pubm embas web scienc scopus screen elig public total twelv articl publish countri retriev risk hcc user nsaid did not nsaid pool hazard ratio hr confid interv ci evid public bias begg test egger test stratifi categori nsaid user nonaspirin nsaid hr ci not aspirin hr ci statist signific hcc nsaid recurr risk hcc hr ci statist signific associ nsaid hcc mortal hr ci taken togeth metaanalysi demonstr nsaid recurr risk hcc;Positive
sulforaphan epigallocatechin gallat restor esr express modul epigenet event breast cell line mdamb systemat review metaanalysi epigenet modif gene activ express alter sequenc environ influenc gene express modif meaning prevent chronic diseas bioactiv compound eg curcumin epigallocatechin gallat egcg isothiocyan eg sulforaphan sfn regul histon acetyl systemat review metaanalysi effect sfn egcg breast bc cell cultur vitro enorm variabl protocol innumer gene involv apoptot cell mdamb cell line effect size es comput ratio mean effect sfn mdamb cell es confid interv focus impact egcg es confid interv effect bioactiv compound sfn egcg effect bc cell restor esr gene express modul epigenet chang event interf growth rate public bias limit generaliz highqual need;Positive
intravas sw colon cell spheroid blood endotheli barrier inhibit clinic flavonoid vitro mechan crc cell penetr blood microvessel endothelia metastasis poor understood blood endotheli cell bec barrier breach crc emboli vitro assay measur becfre area underneath sw cell spheroid call circular chemorepel induc defect ccid appear consequ endotheli retract adapt support western blot eia erod luciferas report assay inhibit alox nfkb sw cell bec attenu ccid fda approv vinpocetin inhibit aloxdepend hete synthesi ketotifen inhibit nfkb carbamazepin fenofibr inhibit hete nfkb attenu ccid format low furesist swr bec model guanfacin nifedipin proadifen inhibit ccid stronger nave sw bec model indic swr cell former silent yet unidentifi gene becam express target cours resist acquisit fenofibr flavonoid hispidulin apigenin medicin plant spice herb fruit attenu ccid format nave resist model fdaapprov foodflavonoid inhibit acquir intravas pathway attenu bec barrierbreach vitro warrant test compound crc model vivo;Positive
monitor exposur infant pollut hous dust health risk babi pollut hous dust greater adult young ingest dust up ten vulner exposur hous dust main exposur sourc infant allergen lead pbdes well sourc exposur pesticid pah gramneg bacteria arsenic cadmium chromium phthalat edc mutagen carcinogen median upper percentil hous dust lead pesticid pah exceed healthbas standard north america earli contact pollut young associ rate chronic ill asthma loss intellig adhd children adult potenti infant live area soil contamin automot industri emiss protect improv home clean hand wash babi live hous built prospect need protect against lead exposur home built even lead exposur risk pollut hous dust soil near hous infant exposur lifetim health cost improv earli learn adult intervent rapid payback larg evid home visit exposur children poor control asthma trigger return invest yr health cost tool famili home visit design dust exposur vacuum cleaner dirt finder hepa filtrat allergi control bed cover highqual door mat hepa air filter infant receiv exposur pollut dust home where spend where famili mitig control normal vacuum clean allow deep dust build up carpet where brought surfac becom airborn result activ carpet vacuum dirt finder allow famili threespot test monitor deep dust reinforc good clean habit motiv famili receiv home visit train outreach worker monitor dust exposur wk cost visit low reduct risk achiev improv home clean result famili receiv home visit mhes chws believ proven intervent exposur infant pollut hous dust recogn much learn improv effect ;Negative
effect propofol haemodynam propofol probabl popular intraven anaesthet daili practic known associ dosedepend cardiovascular compromis effect singl dose propofol cardiovascular eightysix asa ii patient sex schedul elect thorac surgeri enrol midazolam premed patient receiv epidur paravertebr cathet surgeri swanganz cathet map co svi pap pcwp svri pvri lvswi rwswi cpp measur after propofol microg fentanyl spontan respir propofol heart rate pap pvri pcwp decreas map ci svi lvswi rvswi cpp decreas svri unchang result indic propofol moder compromis cardiac contractil afterload right ventricl signific effect coronari perfus pressur cardiovascular compromis clinic insignific caution requir propofol administ larger dose;Negative
acut postischem esr agonist esrbeta agonist improv myocardi recoveri after ischemia reperfus injuri femal heart demonstr improv recoveri compar male protect role estrogen acut postischem betaestradiol attenu myocardi dysfunct unknown esr er mediat acut cardioprotect hypothes postischem infus esr agonist propylh pyrazoletriyl trisphenol ppt esr agonist bishydroxyphenyl propionitril dpn improv myocardi after injuri isol perfus heart langendorff adult male subject minut ischemia minut reperfus heart per random infus perfus ppt dpn nmol throughout reperfus after heart tissu tnf tnf interleukin il beta vascular endotheli growth vegf lactat dehydrogenas ldh postischem nmol ppt improv myocardi addit nmol dpn myocardi recoveri after injuri maximum benefit nmol dose trend level ldh note dpn ppttreat after injuri ppt dpn myocardi tnf ilbeta level myocardi vegf note ppttreat compar control esr esr involv mediat induc rapid cardioprotect after injuri er subtyp benefit male femal myocardi ischemia;Negative
mass balanc pop hazard municip solid wast inciner amount differ persist organ pollut pop input wast inciner compar output case rotari kiln inciner hazard wast grate furnac inciner municip solid wast msw grate furnac coinciner plastic wast electr electron equip weee automot shredder residu asr msw mass balanc pcbs rotari kiln indic pop destroy effect inciner grate furnac sink sourc pcdd fs pcbs depend inciner wast compar total amount pop input output methodolog wherebi amount pop weigh minim risk dose mrds potenc inciner pcdd fs pcbs polyaromat hydrocarbon pah main contributor total weigh pop output msw pcdd fs pbdd fs polybromin diphenyleth pbdes main contributor weigh pop input ratio weigh popinput over output clear indic rotari kiln inciner hazard wast weigh pop sink grate furnac inciner msw weigh pop sink sourc depend popconcentr wast differ output input limit eg asr plastic weee pbdes pcbs coinciner grate furnac clear weigh pop sink;Negative
angiotensin convert enzym inhibitor protect against cardiac complic anthracyclin doxorubicin dox despit cardiac anthracyclin chemotherapeut agent play role breast angiotensinconvert enzym inhibitor acei protect against cardiac patient receiv dox total patient receiv dox mason comprehens clinic univers minnesota multig blood pool imag muga scan echocardiogram perform review patient absolut drop eject fraction ef below compar did not declin ef impact patient variabl concurr medic ef drop logist regress median age year old femal diagnosi breast lymphoma spite baselin ef patient patient signific drop ef dox adjust age oddsratio ef drop associ acei acei protect effect cumul dox dose betablock aspirin did not appear predict protect not statist signific acei dox protect against dox warrant ;Negative
risk colon associ genet polymorph smad genomewid associ gwas smad associ singl nucleotid polymorph snp smad gene rs rs rs gwas larg populationbas casecontrol colon rs associ statist signific risk colon oddsratio confid interv ci linear trend tt genotyp compar cc genotyp cc genotyp rs snp invers associ colon ci tt genotyp signific differ associ polymorph stratifi age site sex famili histori oddsratio smad colon individu report aspirin nonsteroid antiinflammatori ci cc genotyp rs polymorph ci tt genotyp rs polymorph result compar oddsratio ci rs ci individu did not aspirin nonsteroid antiinflammatori signific associ rs snp snps smad result corrobor gwas colon point smad reinforc interest snps gene;Negative
cerb express esr progesteron receptor prognost paramet endometri carcinoma endometri carcinoma ec common malign femal genit tract immunohistochem ihc analys er pr cerbb perform ec case detect stain erbb case statist signific cerbb pr not statist signific cerbb stain er not statist signific differ cerbb histolog grade level cerbb grade case not statist signific cerbb menstrual status myometri invas lymph node status stage surviv addit evid potenti prognost role cerbb prospect control requir valid clinic ;Negative
effect electroacupunctur differ acupoint sevofluran anesthesia patient undergo resect supratentori effect electroacupunctur ea differ acupoint sevofluran anesthet requir resect supratentori speed postoper recoveri total case supratentori resect patient random equal alloc general anesthesia ga eaproxim acupoint eapa eadist acupoint eada supratentori patient anesthet sevofluran surgeri proxim acupoint fengchi gb tianzhu bl cuanzhu bl yuyao exhn formesr acupoint lattesr acupoint penetr needl distant acupoint hegu li waiguan te jinmen bl taichong lr zusan st qiuxu gb craniotomi ea hz hz toler electr strength begin anesthesia till end surgic oper patient anesthet inhal propofol sufentanil microg vecuronium bromid maintain sevofluran endtid sevofluran minimum alveolar mac bispectr index bis speed recoveri record ga endtid anesthesia mainten timepoint post skull drill dura incis intracrani oper eapa timepoint post skull drill skull open dura incis intracrani oper eada mac sevofluran timepoint skull drill eada skull open dura incis intracrani oper dura sutur eapa eada ea proxim distant acupoint expir mac sevofluran anesthesia mainten acceler recoveri after ceas anesthesia supratentori resect patient;Negative
nonsteroid antiinflammatori risk associ nsaid epidemiolog evid effect medic hundr twentyseven subject melanomafre control complet structur interview risk unadjust oddsratio oddsratio nonaspirin nsaid ci subject control after adjust risk ci aspirin user unadjust ci adjust ci pilot evid signific associ analges risk potenti confound conflict report literatur metaanalysi appropri;Negative
subchron oral cardiovascular safeti pharmacolog natur occur prevent activ subchron oral cd receiv daili gavag dose beagl dog receiv daili capsul dose induc minim consist doserel reduct bodi gain femal sex dog statist signific bilirubin level dose clinic hematolog ophthalmolog neurotox batteri organ gross patholog biolog signific evid dose cardiomyopathi microscop chang histopatholog chang dog limit minim infiltr kidney urinari not toxicolog signific cardiovascular safeti pharmacolog telemetri dog reveal evid bodi effect advers effect level noael dog appar cardioprotect activ demonstr potenti activ extend beyond efficaci prevent;Negative
phytochem antioxid capac decoct adenanthera pavonina thespesia populnea decoct prepar bark adenanthera pavonina thespesia populnea herbal formul prescrib sri lanka patient year design phytochem antioxid properti total flavonoid folinciocalteau aluminum chlorid colorimetr gallic content decoct highperform liquid chromatographi antioxid properti diphenylpicrylhydrazyl dpph assay nitric scaveng assay deoxyribos power decoct total flavonoid gallic decoct gallic equival epigallocatechingal equival ec dpph nitric scaveng deoxyribos assay power decoct decoct prepar pavonina populnea nutraceut;Negative
nonaspirin nonsteroid antiinflammatori primari nongastrointestin summari evid evid aspirin effect pharmacodynam nonsteroid antiinflammatori nsaid site discuss literatur uncertainti actual effect nsaid aspirin nongastrointestin summar best avail evid primari effect nonaspirin nsaid nongastrointestin inclus criteria narrat systemat review clinic guidelin not primari control effect nonaspirin nsaid prevent nongastrointestin healthi individu retriev databas guidelinesgov bmj clinic evid trip databas uptod medlin cancerlit embas cinahl isi web scienc scopus independ review elig extract review crosscheck nondupl articl elig report conflict result statist signific associ nonaspirin nsaid risk lung ovari skin head neck risk renal cell carcinoma statist signific methodolog limit confid result did not suffici evid support nonaspirin nsaid primari varieti nongastrointestin scenario caution routin nonaspirin nsaid addit wellconduct control evid issu concern risk exposur;Negative
histogram wholeles enhanc differenti clear cell papillari subtyp renal cell compar histogram voxelbas wholeles wl enhanc qualit regionofinterest roi enhanc discrimin renal cell rcc subtyp clear cell rcc ccrcc papillari rcc prcc institut review boardapprov hipaacompli retrospect patient underw magnet reson mr imag prior surgeri rcc januari januari threedimension fatsuppress tweight gradientecho corticomedullari phase acquisit after agent transfer workstat autom registr semiautom segment rcc perform percent enhanc comput pervoxel sipost sipr sipr where sipr sipost indic signal intens after enhanc wl quantit paramet mean median third quartil enhanc histogram distribut paramet kurtosi skew comput lesion wl enhanc paramet compar roibas qualit regard diagnost accuraci interread agreement differenti ccrcc prcc prccs ccrccs patholog ccrcc wl mean median third quartil enhanc compar prcc hade kurtosi skew third quartil enhanc accuraci area curv discrimin ccrcc prcc accuraci qualit not roi enhanc wl enhanc paramet interread agreement compar roi enhanc qualit discrimin ccrcc prcc wl enhanc histogram feasibl potenti differenti ccrcc prcc;Negative
tapentadol er manag moder sever chronic pain chronic noncancerrel pain larg proport adult popul difficult manag effect opioid analges reliev chronic pain differ etiolog opioid associ effect patient qualiti life lead complianc treatmenttapentadol central act analges mechan action opioid receptor agon norepinephrin reuptak inhibit avail extendedreleas formul manag chronic pain review efficaci tapentadol extend er manag moder sever chronic nocicept neuropath pain efficaci result summar phase tapentadol er patient moder sever chronic osteoarthr knee pain clinicaltrialsgov nct nct low back pain nct pain diabet peripher neuropathi dpn nct oneyear phase tapentadol er patient moder sever chronic osteoarthr pain low back pain nct pool patient osteoarthr knee pain low back pain summari compar toler tapentadol er activ compar oxycodon control cr tapentadol er bid effect manag moder sever chronic osteoarthr knee pain low back pain pain dpn tapentadol er bid compar pain relief oxycodon hcl cr bid chronic osteoarthr knee pain low back pain over up year tapentadol er bid associ improv toler profil gastrointestin toler profil rate discontinu advers eventrel discontinu compar oxycodon hcl cr bid over up year patient osteoarthr knee pain low back pain differ design durat phase limit efficaci result nevertheless demonstr broad tapentadol er differ type nocicept neuropath pain tapentadol er bid moder sever osteoarthr pain low back pain pain dpn efficaci oxycodon hcl cr bid patient osteoarthr low back pain tapentadol er associ gastrointestin toler complianc oxycodon cr tapentadol er option longterm manag chronic pain;Negative
effect fibrin clot inhibitor immunomodulatori efficaci bacillus calmettegurin nonmuscleinvas differ clinic outcom nonmuscleinvas patient take fibrin clotinhibit fci medic aspirin clopidogrel warfarin receiv bacillus calmettegurin bcg compar counterpart not take anticoagul review boardapprov databas queri patient receiv cours bcg patient minimum month followup recurrencefre surviv rfs cystectomyfre surviv surviv diseasespecif surviv kaplanmei stratifi fci status logist regress predict rate bcg fci status patient patient take aspirin clopidogrel warfarin bcg specif fci associ differ cystectomyfre surviv surviv diseasespecif surviv likelihood recurr warfarin clopidogrel rfs patient take aspirin trend rfs not statist signific p contrari postul inhibitori molecular effect fci bcgbind activ did not signific impact bcg efficaci concomit medic bcg aspirin potenti to bcg warrant ;Negative
exfoli sulfon graphen sheet sgss altern graphen graphen deriv synthes particl nontox across g intern sgss mean optic electron microscopi not highresolut transmiss scan electron microscopi reveal variant intern behavior where sgs becam compartment tight bundl cellular organell abil ;Negative
aspirin primari prevent evid aspirin effect primari prevent cardiovascular event chang way inde evid longterm aspirin patient even known cardiovascular diseas theoret argument aspirin prevent cardiovascular event propag thrombus counter evid plaqu haemorrhag vasa vasorum plaqu growth instabl evid aspirin serious bleed brain gut aspirin detract benefit definit cardiovascular benefit angiotensinconvert enzym inhibitor metaanalysi prone bias favour aspirin public bias bias trial endpoint bias interpret metaanalysi not reli prefer adequ power clinic trial unfortun benefit aspirin exist larg inde requir demonstr benefit outweigh risk evid aspirin intrigu reli trial conduct decad ago aspirin dose reliabl evid aspirin fashion dose benefit common clinic set;Negative
despit rise public awar rate white popul rise constant decad systemat improv knowledg biolog pigment cell everyday apigenin quercetin curcumin potenti qualiti compound vari result earli report activ statin fibrat not prove result random clinic trial casecontrol influenc nsaid risk not confirm antitumor activ clinic trial involv care target popul well identif specif biomark prognost predict essenti ;Negative
review summar evid relev hypothes mode action moa ppar activ induc rodent hepatocarcinogenesi gap knowledg moa chemicalspecif mechanist support concord tempor doserespons key event associ ppar activ phthalat ester plastic diethylhexyl phthalat dehp gemfibrozil biolog plausibl human hypothes key event rodent moa ppar activ unlik induc human toxicodynam biolog differ minim effect growth pathway hepatocellular prolifer human hamster guinea pig cynomolg monkey appropri human surrog mice overlap dose level panel conclud signific quantit differ ppar activ induc effect format exist rodent human quantit differ workgroup felt rodent moa not relev human member conclud moa unlik relev human differ level confid perceiv limit quantit mechanist knowledg differ panel member strong support cannot preclud absenc effect unlik exposur scenario;Negative
statin aspirin prevent hepatocellular carcinoma level evid analys larg cohort statin aspirin risk hepatocellular carcinoma hcc natur flaw confound indic immort bias review clinic trial conduct cardiovascular domain effect statin type convinc evid need support potenti prevent effect aspirin hcc clinic trial achiev patient risk;Negative
influenc supplement systemat review second common after lung evid lifestyl play crucial role biolog tumorigenesi good model look agent diseas preval slowli natur long latenc period agent gain consider attent receiv much public media review key evid avail potenti nutrient methodolog review involv pubm search keyword nutrit epidemiolog prevent red meat fat milk intak minimis appear risk fruit veget prevent need draw solid clarifi role patient diagnosi selenium supplement cannot advoc prevent inde dose associ wors prognosi specif evid benefit probiot prebiot wealth evid avail recommend randomis control trial requir need care design confound heterogen popul;Negative
separ chalcon angelica keiskei highspe countercurr chromatographi angelica keiskei shinsun cho edibl plant prevent effect hypertens coronari heart diseas bioactiv chalcon shinsun cho xanthoangelol hydroxyderricin separ simultan highspe countercurr chromatographi twophas solvent system compos nhexaneetoacmeohho nonconsum solvent fraction sephadex lh column chromatographi conduct prestep xanthoangelol puriti nm hydroxyderricin puriti nm puriti nm success purifi extract keiskei structur compound confirm cnmr ;Negative
effect stellat ganglion block hemodynam chang intrapulmonari shunt periop patient esophag study effect stellat ganglion block sgb hemodynam chang intrapulmonari shunt onelung ventil olv thirti asa iii patient undergo elect esophag surgeri random general anesthesia general anesthesia sgb patient receiv left sgb radial arteri cannul arteri blood pressur abp monitor blood sampl swanganz cathet pulmonari arteri via right intern jugular vein local anesthesia ecg map hr cvp continu cardiac output cco index bis continu monitor anesthesia general anesthesia induc propofol sufentanil g rocuronium endobronchi occlud place blind after tracheal indub correct verifi auscult fiberopt bronchoscopi patient mechan ventil ventil condit fio vt respiratori rate adjust maintain petco mmhg twolung ventil tlv olv anesthesia maintain continu infus propofol kgh sufentanil g kgh vecuronium kgh bis maintain blood sampl taken radial arteri sg cathet blood gas interv spontan breath patient awak min after tracheal indub min after patient place later min after min after rib brace min cours olv lung ventil min qs qt calcul svri map hr compar qs qt after patient place later olv calcul qs qt t pao after olv start reach lowest level gradual signific differ qs qt pao point sgb effect suppress work stabl blood dynam not qs qt arteri olv sgb safe techniqu anesthesia general thorac surgeri;Negative
mediterranean low grade inflamm result molisani low grade inflamm rais absenc overt symptom recogn risk chronic diseas cardiovascular cerebrovascular neurodegen diseas low grade inflamm mitig health promot behaviour healthi eat pattern physic activ bodi mainten tobacco cessat date larg scale focus circul littl evid avail cellular biomark molisani prospect cohort recruit men women age year general popul molis region southern italian area purpos genet environment risk protect cardiovascular cerebrovascular diseas cohort score low grade inflamm plasmat creactiv protein cellular leukocyt platelet count granulocyt ratio biomark propos valid score account effect overcom potenti bias link multicollinear variabl notic molisani address tradit mediterranean platelet leucocyt count cellular biomark low grade inflamm review paper discuss main deriv molisani associ low grade inflamm mediterranean eat pattern emphasi associ ;Negative
effect statin aspirin patholog complet rate neoadjuv chemoradi rectal retrospect potenti impact statin aspirin acut patholog complet pcr rate rectal patient receiv neoadjuv longcours radiat lcrt concurr retrospect review perform patient undergo neoadjuv lcrt rectal adenocarcinoma region servic septembesr june demograph detail date radiolog tnm stage diagnosi medic taken rt lcrt surgic histolog pcr lcrt neoadjuv lcrt administ patient rectal period concurr omit signific comorbid tnm stage radiolog diagnosi patient lcrt take statin take aspirin patient achiev pcr surgeri logist regress pcr not associ statin aspirin nsaid tstage nstage signific correl statin aspirin rectal actuari maximum rectal not differ statin user nonus larger retrospect seri did not improv pcr rate statin aspirin rectal patient undergo lcrt potenti benefit set best prospect larg random trial;Negative
sclerosi ms demyelin neurodegen diseas neurolog disabl young adult indic proremyelin effect potenti addit benefit sclerosi;Negative
proinflammatori cytokin senior hors vitro senior hors exhibit chronic lowgrad inflamm system term inflammag inflamm associ afflict common hors lamin osteoarthr common nonsteroid antiinflammatori nsaid flunixin meglumin phenylbutazon longterm nsaid result effect bioactiv curcuminoid quercetin pterostilben hydroxypterostilben heparin blood via jugular venipunctur senior hors peripher blood mononuclear cell pbmc isol ficol densiti gradient pbmc incub curcuminoid quercetin pterostilben hydroxypterostilben dissolv dmso achiev aforement pbmc last incub period phorbol myrist acet pma ionomycin brefeldin bfa pbmc stain intracellular via flow cytometri oneway varianc anova viabil pbmc incub compound compar pbmc incub dmso alon control cell viabil did not differ control viabil did not differ control perform effect common nsaid cytokin senior hors vitro chronic inflamm hors;Negative
updat evid endoscop resect earli japan endoscop resect earli egc play central role egc japan still room improv necessari summar knowledg japan improv conduct pubm search relev articl year until septembesr keyword endoscop endoscop submucos dissect endoscop mucos resect polypectomi filter articl type clinic clinic trial articl automat keyword polypectomi articl endoscop mucos resect articl endoscop submucos dissect articl endoscop articl relev articl japanes chosen articl categor equip prepar sedat complic prevent therapeut outcom co insuffl propofol sedat prevent postendoscop submucos dissect esd ulcer bleed achiev postesd ulcer heal intens longterm outcom endoscop mucos resect esd report favor outcom endoscop resect egc still ideal pursu reliabl safer faster minim invas ;Negative
variat applic low dose rate intracavitari brachytherapi cervic prospect know effect variat applic dose receiv volum organ rectum correl variat clinic outcom patient histolog proven cervic undergo intracavitari brachytherapi icbt octobesr decembesr subject pair orthogon xray film taken prior load sourc after remov sourc patient up per rtog criteria median durat insert hour median up period month translat variat applic patient sd patient later anteroposterior direct rotat variat degre sd patient transvers sagitt plane detail sourc movement chang median dose point point point rectum rectum rectal variabl rectal point rectal pearson later displac anteroposterior displac rectal beta angl geometr icbt applic structur vari cours low dose rate brachytherapi sourc movement result signific dose alter term rate complic impact cure rate need futur;Negative
polyphenolinspir facil construct smart assembl atp phrespons mr optic imag phototherm smart assembl attract interest area novel stimulirespons theranost commerci avail natur tannic ta iron nanoparticl fe nps util model construct smart magnet assembl polyphenolinspir npsphenol selfassembl nps ta interest magnet assembl special disassembl adenosin triphosph stronger affin fe nps ta replac surfac coordin ta disassembl facilit environ henc remark chang transvers relax potent turnon fluoresc fl signal assembl specif sensit magnet reson fl dualmod imag phototherm after intraven inject assembl success employ work not selfassembl nps open new insight facil construct versatil assembl extend biomed applic;Negative
novel polymorph tmema gene system lupus erythematosus chines han popul associ singl nucleotid polymorph snps six gene irf tmema ikzf ormdl gsdmb zpbp system lupus erythematosus sle chines han popul sampl carri out casecontrol patient sle healthi control autoimmun diseas genet isol blood subject standard phenolchloroform tagsnp genotyp panel han chines beij hapmap project haploview program genotyp assay conduct sequenom massarray iplex gold platform frequenc allel genotyp calcul haplotyp perform genotyp frequenc rs rs differ sle patient healthi control compar common homozyg genotyp ct genotyp rs ac genotyp rs risk sle snps locat tmema gene associ sle suscept chines han popul;Negative
tpmt comt acyp genet variant paediatr patient cisplatin induc ototox cisplatin ototox children catecholomethyltransferas comt thiopurin methyltransferas tpmt aycp genet variant associ ototox contradictori associ care phenotyp cohort uk children perform systemat review metaanalysi recruit children uk centr retrospect cohort design particip clinic phenotyp care genotyp perform acyp rs tpmt rs rs rs comt rs rs variant ctcae grade hear loss worst ear ear chang grade hear loss diagnos worst ear versus ear tpmt comt singlenucleotid polymorph snps associ ototox acyp snp rs associ ototox worst ear metaanalysi report pool oddsratio oddsratio statist signific comt snp rs confid interv acyp snp rs confid interv associ acyp polymorph cisplatin induc ototox not tpmt comt metaanalysi statist signific comt rs acyp rs snps grade hear children asymmetr hear loss requir addit clarif;Negative
effect hydroethanol root extract zanthoxylum zanthoxyloid hematolog paramet cyclophospamid anim pretreat oral dose extract coadminist cyclophosphamid ld extract antioxid enzym assay cat anim cp compar cp cp gpx cp compar cp control sod cp compar control wbc cp cp cp cp administ compar control ldl chol cp cp;Negative
childhood measur adipos young girl compound environment potenti endocrinedisrupt capabl longitudin associ childhood exposur manmad natur sourc measur adipos girl enrol research program baselin age year urinari creatinin bodi mass index height waist circumfer percent bodi fat measur annual semiannu linear mixedeffect regress estim baselin tertil chang girl adipos measur age year enterolacton invers associ bodi mass index waist circumfer percent bodi fat dichlorophenol associ measur nonmonoton associ triclosan girl adipos effect modif baselin overweight status triclosan associ adipos overweight girl result exposur specif childhood influenc adipos adolesc;Negative
primari biliari cholang advanc manag diseas primari biliari cholang known primari biliari cirrhosi rare diseas women fifth seventh decad life chronic autoimmun diseas damag interlobular bile duct lead ductopenia chronic cholestasi bile retent even diseas usual long asymptomat phase slow patient faster cirrhosi complic year mortal greater diseas human immunodefici virus virus coinfect breast ursodeoxychol avail today even effect counteract diseas patient approxim not abl decreas effect alkalin phosphatas surrog diseas activ obetichol receiv european medicin agenc condit approv add patient non respond intoler ursodeoxychol paper illustr opinion work compos clinic pharmacologist gastroenterologist hepatologist specif expertis primari biliari cholang patient associ state art futur perspect diseas manag agreement document reach expert meet;Negative
sedat endoscopi room oper room endoscop submucos dissect neoplasm upper gastrointestin tract perform compar safeti sedat endoscop submucos dissect esd endoscopi room versus oper room total patient gastrointestin underw esd januari decembesr retrospect review patient underw esd endoscopi room propofol versus oper room propofol patient procedur characterist advers event outcom compar patient characterist age comorbid size histolog not differ esd procedur compar anesthesia equival signific differ advers event esd procedur desatur occur recoveri after esd longer vs min decreas desatur rate shorter recoveri after esd advantag sedat oper room propofol compar sedat endoscopi room warrant advantag safe effect esd upper gastrointestin neoplasm oper room;Negative
oncolog communiti reject bias come repurpos measur propos combat challeng financi care strategi lowerpr instead expens altern oncolog communiti ignor readili reject cheaper care compar expens altern commentari exampl lowerpr reject ignor oncolog communiti expens where persist optim despit clinic trial result argu held rigor standard not skeptic absenc sound evid suspens prematur judgement happen case repurpos ;Negative
induc senesc compound senolyt face nrfactiv adjuv reactiv senesc clearanc senesc intervent describ vitro vivo effect cellular senesc light avail literatur conclud mean potenti adjuv natur compound human take account exist few clinic trial uncertain result need therapeut potenti compound display senolyt activ;Negative
endocrin disrupt compound vertebr neural network multielectrod array bisphenol bisphenol bpa bisphenol bps polymer agent plastic numer everyday classifi endocrin disrupt compound edc estradiollik properti longterm exposur edc even low dose link health defect behavior disord infertil greater vulner earli development period effect bpa neuron vitro neuron network deriv earli chick embryon brain model system avail market variat electrod type qualiti electrod array softwar basic principl across differ system limit twodimension vitro cultur mea system improv enabl vivo network activ brain slice detail protocol embryon exposur record neuron network activ synchroni result;Negative
intak food sourc mexican teacher cohort descript intak flavonoid publish europ usa insuffici still avail latinamerican countri where differ type food consum differ habit goal crosssect estim intak grand total total per subclass individu compound main food sourc mexican women mexican teacher cohort femal teacher year older twelv state mexico urban rural area period valid ffq individu intak estim food phenolexplor databas median total intak baja california lowest yucatan main consum  total flavonoid  intak subclass stilben lignan insignific coffe fruit food sourc flavonoid intak total differ individu estim fortytwo consum amount larg consum caffeoylquin ferul hesperidin proanthocyanidin larg heterogen intak individu mexican women moder heterogen across mexican state main food sourc differ state;Negative
mucosa human detrusor impair contract betaadrenoceptormedi relax elucid impact mucosa detrusor muscl forc contract stimulatori condit relax catecholamin detrusor tissu patient undergon cystectomi strip intact mucosadenud muscl set up forc measur prepar precontract kcl carbachol electricfield ef precontract strip relax catecholamin absenc presenc subtypeselect betaadrenoceptor ar blocker cgp betaar ici betaar betaar forc kcl mm carbachol m ef larger absenc mucosa intact muscl strip forc contract mucosadenud strip detach urothelium incub chamber low intact strip noradrenalin relax precontract detrusor strip larger extent denud intact strip cgp did not noradrenalin induc relax denud intact strip ici did not influenc noradrenalin induc relax denud strip abolish differ denud intact strip antagon relax effect noradrenalin slight smaller intact denud strip mucosa human detrusor strip impair forc kcl carbachol ef mucosa blunt relax effect catecholamin latter effect not involv betaar betaar betaar mediat relax human detrusor;Negative
disord innat human age effect nutraceut declin age account risk infect chronic diseas autoimmun human innat adapt compromis age peopl attempt correct dysfunct goal modern medicin review special emphasi place age innat potenti modifi impair innat princip nutraceut illustr micronutri preprobiot elder clinic trial abov scanti;Negative
spot novel streamlin microarray platform cellular trna level place transfer rna trna housekeep molecul heart fundament cellular embryon discoveri conting concomit abl deliv highqual trna profil describ proof concept escherichia coli coli origin trna platform name spot streamlin platform trna approach compris step coli cultur spike radioact orthophosph second label total rnas trizolextract third rna sampl hybrid inhous print microarray spot signal proxi trna level quantifi phosphorimag featur reproduc specif trna subpopul dynam sensit overexpress specif trna spot not requir amplif postextract label adapt organ modular easili streamlin popular techniqu polysom fraction profil trnas interact ribosom activ engag translat biolog relev discuss regard codon usag trna gene copi genom;Negative
influenc freezethaw cycl rna integr gastrointestin match adjac tissu compar rna express profil adjac noncancer tissu research highqual rna essenti consist reliabl result identif impact freezethaw cycl qualiti rna pair adjac tissu still influenc freezethaw cycl rna integr histomorpholog pair adjac noncancer tissu gastrointestin match adjac noncancer tissu frozen thaw twice extract rna total rna sampl extract trizol reagent rna integr rna integr rin agil bioanalyz light microscopi tissu morpholog rin sampl tend correl frequenc freezethaw rin cutoff rna extract tissu not qualifi after freezethaw moreov rna extract adjac noncancer tissu nonqualifi rin score after freezethaw except tissu microscop sampl display qualifi tissu morpholog regardless freezethaw frequenc freezethaw rna integr not tissu morpholog gastrointestin pair adjac noncancer tissu furthermor rna extract adjac noncancer tissu easili degrad tissu;Negative
prevent supplement fresh preserv peach attenu ccl induc inflamm tissu damag elabor compar prevent effect differ peachderiv preserv fruit syrup preserv pulp peach ppp fresh peel pulp peel fresh pulp peach fpp model renal inflamm induc carbon tetrachlorid ccl tissu damag carbonyl thiobarbitur reactiv sulfhydril antioxid enzym activ catalas superoxid dismutas paramet tnf tnf interleukin il beta level receptor advanc glycat endproduct rage nuclear nfkbp immunocont demonstr peel ppp fpp daili oral gavag confer protect against ccl induc antioxid enzym antioxid antiinflammatori effect associ abund carotenoid peachderiv enrich freshfruitderiv prepar peel fpp ppp result evid supplement peach protect against organ interest candid antioxidantenrich food;Negative
septic endarter intraarteri cathet outbreak ii risk clinic featur manag iii guidelin prevent cluster case staphylococc septic endarter origin percutan insert brachial arteri cathet region prompt epidemiolog clinic bacterem infect associ therapeut modal nine case over year period catheter staphylococcus aureus cluster discontinu hexachlorophen scrub extrem prior cannul phagetyp case patient own strain staphylococcus infect produc distinct clinic syndrom facilit implic cathet genesi fever occur patient receiv intraarteri earli local pain hemorrhag osler node distal later local inflamm purul sign system sepsi less equal durat cannul did not influenc suscept infect difficult cannul need reposit cathet prior radiat leukopenia less hypoalbuminemia less associ septicemia month implement specif control measur catheterrel septicemia catheter less guidelin prevent manag infect ;Negative
ntp toxicolog carcinogenesi pentachlorophenol cas feed pentachlorophenol herbicid algicid defoli wood preserv germicid fungicid molluscicid pentachlorophenol nomin nation institut carcinogen test widespread wood preserv potenti enter environ pentachlorophenol residu soil water air sampl food human anim tissu bodi fluid likelihood bioaccumul environ pentachlorophenol persist soil halflif up year technic report result year pentachlorophenol perform ntp bcf mice male femal expos pentachlorophenol approxim pure feed year genet toxicolog conduct vitro salmonella typhimurium cultur chines hamster ovari cell vivo mous bone marrow cell male femal ppm pentachlorophenol equival averag daili dose approxim pentachlorophenol bodi male femal feed except male femal expos ppm surviv until end final mean bodi bodi gain male expos ppm femal expos ppm less control expos ppm lost feed consumpt ppm male less control throughout absolut ppm male expos femal greater control compar control minim mild hepatocyt degener male femal expos ppm greater centrilobular hepatocyt hypertrophi ppm year male femal fed ppm pentachlorophenol equival averag daili dose approxim stopexposur male femal receiv ppm equival feed after anim receiv undos feed remaind year male femal control ppm month surviv bodi feed consumpt year surviv ppm male greater control mean bodi ppm male femal general less control exposur pentachlorophenol discontinu mean bodi ppm male femal control end mean bodi control general feed consumpt expos control patholog year malign mesothelioma origin tunica vaginali greater ppm male control exceed histor control nasal squamous cell carcinoma control male ppm male ppm male ppm male year ppm male exceed histor control month interim centrilobular hepatocyt hypertrophi ppm male femal hepatocyt cytoplasm vacuol ppm male greater control year nonneoplast lesion hepatodiaphragmat nodul hepatocyt cystic degener expos ation expos male basophil foci ppm male compar control genet toxicolog pentachlorophenol percnt pure test salmonella typhimurium strain ta ta ta ta dose up mug plate induc hamster signific revert coloni strain activ test cytogenet effect cultur chines hamster ovari cell pentachlorophenol weak sister chromatid exchang chromosom aberr sister chromatid exchang test weak mug absenc sister chromatid exchang note chromosom aberr test pentachlorophenol induc signific frequenc aberr cell presenc dose mug vitro result test chromosom aberr frequenc micronucl erythrocyt note bone marrow male mice administ pentachlorophenol intraperiton inject hour interv dose administ mice lethal condit year feed evid carcinogen activ pentachlorophenol male femal fed ppm evid carcinogen activ pentachlorophenol male feed ppm year control feed year stopexposur mesothelioma nasal squamous cell carcinoma evid carcinogen activ pentachlorophenol femal feed ppm year maintain control feed year stopexposur male femal recov transitori reduct bodi gain end year male surviv compar control;Negative
count miss metaboliteintens set measur analyt perform metabolom platform metabolom requir quantit individu entir sampl set unfortun miss intens sampl common miss profound influenc metabolom result extent miss metabolom set paramet measur analyt perform techniqu work report scope miss robust fill miss isotop label cil lcms metabolom platform unlik convent lcms cil lcms quantifi differ individu compar sampl mass spectral peak intens ratio peak pair mixtur differenti label sampl peakpair featur uniqu mean extract intens inform raw mass spectra approach peakpair peak algorithm isom lcms set generat csv file tabl id peak ratio inform ie metaboliteintens tabl zerofil program freeli avail mycompoundidorg automat miss csv file go back raw lcms peak pair calcul intens ratio enter ratio tabl miss low abund peak pair demonstr perform technic replic set human urin metabolom furthermor propos standard approach count miss replic set way gaug extent miss metabolom platform final illustr appli zerofil program conjunct dansyl cil lcms lead mark improv signific differenti patient control metabolom subject;Negative
synthesi fedaa new pet imag probe peripher benzodiazepin receptor express peripher benzodiazepin receptor pbr associ neuroinflamm daa fedaa promis radioligand positron emiss tomographi pet imag pbr design new radiolabel analog daa fedaa fedaa pet imag pbr express brain precursor nfluorophenoxyphenyl nfluoroethoxi hydroxybenzylacetamid synthes step moder yield precursor label chotf isol pressur liquid chromatographi hplc purif target radioligand nfluorophenoxyphenyl nfluoroethoxi methoxybenzylacetamid fedaa radiochem yield decay correct end bombard eob co specif activ radiotrac gbq micromol end synthesi eo;Negative
applic sigmoid sinus tunnelpack pushpack inferior petrous sinus microsurg manag jugular paraganglioma outcom microsurg jugular paraganglioma control bleed inferior petrous sinus retrospect patient review singl univers hospit fortythre patient jugular paraganglioma diagnos past year clinic surgic control intraop blood loss intraop manag facial nerv preoper postop central nerv twentysix patient underw microsurg eighteen six cde gross total resect achiev patient mean blood loss surgeri recurr rate over mean followup month new facial palsi cranial nerv deficit occur patient infratempor fossa approach type sigmoid sinus tunnelpack pushpack techniqu facilit control bleed inferior petrous sinus improv outcom microsurg jugular paraganglioma;Negative
exact statist test carcinogen effect anim bioassay ii ageadjust test statist discuss applic anim carcinogenesi bioassay test general null hypothesi frequenc independ level endpoint sex bioassay condit surviv propos earlier farrar crump fundam appl toxicol involv test statist standard statist hypothesi test signific random refin introduct exact incident test analog asymptot test hoel walburg natl inst take account differ rate result differ surviv independ addit consider test statist test propos sensit specif case where endpoint sex applic procedur result nation toxicolog program ntp bioassay concern decabromodiphenyl iodin glycerol illustr sensit test differ test statist distinct altern hypothes compar qualit ntp strength evid carcinogen effect bioassay result clarifi otherwis equivoc evid carcinogen difficulti discuss relev construct exact fatal incident test analog test peto et al iarc monogr suppl;Negative
birth cohort papillari thyroid unit state papillari thyroid report past decad reason unknown pattern papillari thyroid unit state compon birth cohort defin year birth period age trend diseas nation institut surveil epidemiolog end result program conduct univari ageperiodcohort model birth cohort pattern age period cohort effect trend over clear birth cohort pattern men women result ageperiodcohort model period effect appear impact trend birth cohort effect explain trend papillari thyroid carcinoma period women period effect like advanc diagnost techniqu medic detect thyroid nodul explain specul birth cohortrel chang environment exposur exposur diagnost xray polybromin diphenyl ether contribut papillari thyroid past decad;Negative
partial hepatectomi cirrhot right later total patient cirrhot solitari hepatocellular carcinoma hcc locat later right lobe underw surgeri techniqu clamp finger dissect oper mortal acut chronic failur total oper minut actual resect minut averag amount blood transfus procedur preoper serum bromsulphalein retent rate proportion reflect postop peak serum conjug bilirubin resect specimen less gm less enzym sgot sgpt lactat dehydrogenas cell postop promin patient hypotens hypotens less enzym level return preoper level fourteenth postop excretori capac cell measur serum bromsulphalein retent rate still abnorm less took month declin level still exceed preoper level less partial hepatectomi cirrhot clamp finger dissect simpl rapid techniqu serious effect;Negative
applic silver stain cytolog specimen neuroendocrin metastat cytolog specimen neuroendocrin metastat regard silver stain properti after applic argentaffin argyrophil stain techniqu masson grimelius seviermung content serotonin intestin carcinoid presenc demonstr cytolog argentaffin individu cell formalin fixat prerequisit stain melanin malign cell display argentaffin irrespect fixat air dri formalin bouin fluid acetonealcohol serotonin melanin distinguish cytolog sampl neuroendocrin masson argentaffin differ fixat nonargentaffinposit neuroendocrin weak stain unreact grimelius argyrophil techniqu seviermung argyrophil techniqu gave disturb nonspecif background stain difficult interpret cytolog sampl grimelius appear silver stain neuroendocrin cell cytolog materi irrespect hormon content argentaffinposit argentaffinneg sampl stain least degre;Negative
cell blot techniqu stain microscop cell blot nitrocellulos paper standard cytolog histolog stain procedur success appli nitrocellulos nc paper stain spectrum cell type blot stain procedur papanicolaou hematoxylin eosin immunoperoxidas techniqu type consist suspens monolay cultur well fresh prepar nontumor tissu suspend cell manual blot nc paper fix fixat propanol neutralbuff formalin carnoy solut bouin fluid fixat stain abov after stain nc paper dehydr absolut propanol transpar soak xylen mount perman mount medium permount glass slide microscop proteinblot capac nc paper schleicher schuell compar convent cell blot media millipor gelman cellulos acet bovin serum albumin dotblot nc cellulos acet filter stain protein amido black cytolog histolog stain amido blackstain filter dehydr absolut propanol transpar xylen mount permount densitometr trace indic nc paper bound amount protein feasibl cytolog histolog stain techniqu nc paper proteinblot capac allow situ stain microscop babi hamster kidney cell bind fibronectin blot nc paper signific techniqu cell biolog research discuss;Negative
cytolog diagnosi medullari carcinoma thyroid seviermung silver stain calcitonin immunocytochemistri medullari carcinoma thyroid preoper diagnos ultrason guid fine needl aspir biopsi after cytocentrifug cell display dens cytoplasm silver granul seviermung techniqu appli airdri acetoneethanolfix sampl obvious calcitonin immunoreact after fixat bouin fluid prove identif nonpalp metastas recurr medullari carcinoma thyroid cytolog type medullari thyroid carcinoma cell difficult routin stain;Negative
sort out mixup proven tissu section confirm pcr microsatellit standard identif system usual ensur biopsi materi correct associ patient sometim unexpect proven proof origin tissu sampl question tissu mislabel contamin tissu patient techniqu confirm tissu proven compar tissu gender abo blood weak confirmatori power dnabas polymeras chain pcr techniqu report pair formalinfix paraffinembed micron tissu section patient whom carcinoma biopsi section sequenti biopsi sequenti biopsi autopsi tissu result sampl code addit case fragment patient tissu block benign tissu patient fragment hematoxylinandeosinstain section separ scrape off glass slide tissu clinic case suspect mislabel suspect carryov malign tissu short tandem repeat sequenc str microsatellit pair repeat vari repeat individu variat polymorph pcr panel strs acpp int cyp chromosom isol sampl after xylen deparaffin proteinas digest amplifi radioact pcr primer give size amplifi electrophores denatur polyacrylamid gel dri autoradiograph segment success extract sampl fix bouin fluid compar allel size panel tissu pair bouin pair success match fragment correct assign clinic problem solv strs inform robust well suit pcr portion tissu section effect confirm proven benign malign biopsi autopsi materi;Negative
